Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Stoke Therapeutics Inc (STOK)
NASDAQ:STOK
RESEARCH TOOLSreports
STOK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.20 - $17.58
Previous CloseN/A
Volume337.58K
Average Volume (3M)875.63K
Market Cap
$514.31M
Enterprise Value$458.46M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Mar 05, 2025EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.10
Shares Outstanding52,966,976
10 Day Avg. Volume800,016
30 Day Avg. Volume875,633
Standard Deviation0.22
R-Squared0.05
Alpha-0.00356
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)30.72
Price to Cash Flow (P/CF)-6.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit52.22
Enterprise Value/Ebitda-3.97
Forecast
1Y Price Target
$28.40Price Target Upside205.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Stoke Therapeutics News
PremiumCompany Announcements
Stoke Therapeutics Partners with Biogen for Zorevunersen
PremiumCompany Announcements
Stoke Therapeutics Gains Regulatory Alignment for Phase 3 Study---
Bulls Say, Bears Say
Bulls Say
Market OpportunitiesStoke retains exclusive rights to zorevunersen in the US, Canada, and Mexico, securing lucrative market opportunities.
Partnership And CollaborationThe collaboration with Biogen provides crucial validation and capital, eliminating the need for further financing.
Bears Say
Investor SentimentThe stock is trading off ~15% as investors are disappointed that there is no type of accelerated approval based on a potential interim look versus the announced study timeline that will result in data disclosed in 2H27.
---
Ownership Overview
45.88% Insiders
10.74% Mutual Funds
2.55% Other Institutional Investors
29.31% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
STOK FAQ
What was Stoke Therapeutics Inc’s price range in the past 12 months?
Stoke Therapeutics Inc lowest stock price was $5.20 and its highest was $17.58 in the past 12 months.
What is Stoke Therapeutics Inc’s market cap?
Stoke Therapeutics Inc’s market cap is $514.31M.
When is Stoke Therapeutics Inc’s upcoming earnings report date?
Stoke Therapeutics Inc’s upcoming earnings report date is Mar 05, 2025 which is in 12 days.
How were Stoke Therapeutics Inc’s earnings last quarter?
Stoke Therapeutics Inc released its earnings results on Nov 05, 2024. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.52 by $0.05.
Is Stoke Therapeutics Inc overvalued?
According to Wall Street analysts Stoke Therapeutics Inc’s price is currently Undervalued.
Does Stoke Therapeutics Inc pay dividends?
Stoke Therapeutics Inc does not currently pay dividends.
What is Stoke Therapeutics Inc’s EPS estimate?
Stoke Therapeutics Inc’s EPS estimate is -0.53.
How many shares outstanding does Stoke Therapeutics Inc have?
Stoke Therapeutics Inc has 52,966,976 shares outstanding.
What happened to Stoke Therapeutics Inc’s price movement after its last earnings report?
Stoke Therapeutics Inc reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.52. Following the earnings report the stock price went down -0.382%.
Which hedge fund is a major shareholder of Stoke Therapeutics Inc?
Currently, no hedge funds are holding shares in STOK
---
Stoke Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.40 (205.38% Upside)
$28.40 (205.38% Upside)
Blogger Sentiment
Bullish
STOK Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $23.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
76.47%
12-Months-Change
Fundamentals
Return on Equity
-52.06%
Trailing 12-Months
Asset Growth
22.27%
Trailing 12-Months
Company Description
Stoke Therapeutics Inc
Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. It is a biotechnology firm that focuses to increase gene expression to treat severe genetic diseases, including genetic conditions affecting the central nervous system, eye, ear, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
---
STOK Stock 12 Month Forecast
Average Price Target
$28.40
▲(205.38% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Ionis Pharmaceuticals
―
Wave Life Sciences
―
Intellia Therapeutics
―
Moderna
―
Best Analysts Covering STOK
1 Year
1 Year Success Rate
8/15 ratings generated profit
1 Year Average Return
+40.13%
reiterated a buy rating 3 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +40.13% per trade.
---